Ngā hua rapu - Li-Gong Lu

  • E whakaatu ana i te 1 - 1 hua o te 1
Whakamahine hua
  1. 1
    Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway

    Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway mā Qing-Feng Xiang, Mei-Xiao Zhan, Yong Li, Hui Liang, Cong Hu, Yao-Ming Huang, Jing Xiao, Xu He, Yong-Jie Xin, Min-Shan Chen, Li-Gong Lu

    I whakaputaina 2019-12-01

    Sorafenib is an oral multikinase inhibitor that has become an established therapeutic approach in advanced hepatocellular carcinoma (HCC). However, the benefit of sorafenib in clinical therapy is often affected by drug resistance. Therefore, it is important to explore the mechanisms underlying soraf...

    Whakaahuatanga katoa

    Whiwhi kuputuhi katoa
    Tuhinga

    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: